THBD与PROCR多态性对蛋白C通路抗凝反应的体内外影响
在73名参与者中采用重组活化凝血因子VII激发凝血并检测8小时凝血酶标志物与活化蛋白C,另在43名参与者中进行内皮集落形成细胞体外实验。结果显示PROCR 655A>G携带者APC反应降低,THBD 1418C>T携带者因TAT AUC降低而APC/TAT比值升高,FVL携带者比值升高,提示常见THBD和PROCR变异可调节蛋白C通路功能。
要点
- PROCR 655A>G携带者体内APC反应降低,与既往VTE者类似。
- THBD 1418C>T携带者APC/TAT比值升高,源于TAT AUC降低。
- APC反应可作为检测FVL以外细微遗传效应的敏感终点。
核心结论
- 常见THBD和PROCR变异在体内调节蛋白C通路功能,APC反应是检测FVL以外细微遗传效应的敏感终点。
研究设计与样本
- 在73名参与者中使用重组活化因子VII(15 μg/kg)标准化体内凝血激活,检测8小时凝血酶标志物和活化蛋白C。
- 在43名参与者中进行基于内皮集落形成细胞的体外实验。
主要发现
- 体内APC AUC与TAT AUC比值模型拟合最佳(调整R2=0.345)。
- 既往VTE者APC反应中位数0.13 vs 0.26,PROCR 655A>G携带者0.11 vs 0.26,均较低。
- FVL携带者APC反应中位数0.32 vs 0.14,THBD 1418C>T携带者0.38 vs 0.13,均较高。
- THBD 1418C>T效应由TAT AUC降低驱动(30.6 vs 82.7 pmol×h/L),PROCR 655A>G效应反映APC AUC较低(8.6 vs 10.7 pmol×h/L)。
- 体外APC AUC/凝血酶AUC比值在既往VTE和PROCR 655A>G者中较低,FVL者中较高,与THBD 1418C>T无关;PROCR 4678C>G无体内外关联。
临床怎么用
- 对于既往VTE且无已知遗传风险因素者,可考虑评估PROCR 655A>G和THBD 1418C>T等变异对蛋白C通路功能的影响。
- APC反应比值可作为研究环境中评估遗传变异功能效应的敏感终点,但尚需进一步验证用于临床决策。
局限性
- 样本量较小(体内73人、体外43人),结果需更大规模研究验证。
- 研究采用重组活化因子VII激发凝血,可能不完全反映生理性凝血激活状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism (VTE) is multifactorial, and established hereditary risk factors explain only part of heritable risk. The protein C (PC) pathway is central to anticoagulant control, and common variants in thrombomodulin and endothelial PC receptor genes (THBD, PROCR) have been proposed as modulators. In 73 participants, we used standardized in vivo coagulation activation with recombinant activated factor VII (15 μg/kg) and measured thrombin markers and activated PC (APC) over 8 hours. Endothelial colony-forming cell-based ex vivo experiments were performed in 43 participants. In vivo, the ratio of APC area under the curve (AUC) to thrombin-antithrombin complex (TAT) AUC, which reflects the endogenous anticoagulant response relative to thrombin generation, provided the best model fit (adjusted R2 = 0.345). The APC response was lower in individuals with previous VTE (median, 0.13 vs 0.26) and PROCR 655A>G carriers (0.11 vs 0.26), but higher in factor V Leiden (FVL) carriers (0.32 vs 0.14) and THBD 1418C>T carriers (0.38 vs 0.13). The THBD 1418C>T effect was driven by reduced TAT AUC (30.6 vs 82.7 pmol × h/L), whereas the PROCR 655A>G effect reflected a lower APC AUC (8.6 vs 10.7 pmol × h/L). Ex vivo, the APC AUC/thrombin AUC ratio was lower with previous VTE and PROCR 655A>G, higher with FVL, and not associated with THBD 1418C>T. No in vivo or ex vivo association was observed for PROCR 4678C>G. This study provides in vivo evidence that common THBD and PROCR variants modulate PC pathway function, establishing the APC response as a sensitive end point for subtle genetic effects beyond FVL.
引用
- Reda S, Schwarz N, Eckert SF, et al. In vivo and ex vivo impact of THBD and PROCR polymorphisms on the anticoagulant response of the protein C pathway. Blood Adv. 2026. PMID: 42480122. doi:10.1182/bloodadvances.2025018733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。